Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
3 recherche sur le mot-clé 'Antipsychotic'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 47-7 (July 2017)
[article]
Titre : Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.2290-2294 Langues : Anglais (eng) Mots-clés : Autism Autism spectrum disorder Metformin Antipsychotic Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314
in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294[article] Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur . - p.2290-2294.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294
Mots-clés : Autism Autism spectrum disorder Metformin Antipsychotic Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders / Selma TURAL HESAPCIOGLU in Research in Autism Spectrum Disorders, 72 (April 2020)
[article]
Titre : Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Selma TURAL HESAPCIOGLU, Auteur ; Mehmet Fatih CEYLAN, Auteur ; Meryem KASAK, Auteur ; Cansu P?nar SEN, Auteur Article en page(s) : p.101520 Langues : Anglais (eng) Mots-clés : Antipsychotic Aripiprazole Autism Spectrum Disorders Irritability Olanzapine Risperidone Index. décimale : PER Périodiques Résumé : Background The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5?10 mg/day) in comparison with 42 risperidone (1?4 mg/day) and 40 aripiprazole (3?15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X2 = 26.9, p < 0.0001; X2 = 20.8, p < 0.0001; X2 = 8.4, p = 0.01, respectively). Discussion Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD. En ligne : https://doi.org/10.1016/j.rasd.2020.101520 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421
in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101520[article] Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Selma TURAL HESAPCIOGLU, Auteur ; Mehmet Fatih CEYLAN, Auteur ; Meryem KASAK, Auteur ; Cansu P?nar SEN, Auteur . - p.101520.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 72 (April 2020) . - p.101520
Mots-clés : Antipsychotic Aripiprazole Autism Spectrum Disorders Irritability Olanzapine Risperidone Index. décimale : PER Périodiques Résumé : Background The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5?10 mg/day) in comparison with 42 risperidone (1?4 mg/day) and 40 aripiprazole (3?15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X2 = 26.9, p < 0.0001; X2 = 20.8, p < 0.0001; X2 = 8.4, p = 0.01, respectively). Discussion Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD. En ligne : https://doi.org/10.1016/j.rasd.2020.101520 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421 Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder / Covadonga M. DIAZ-CANEJA in Journal of Child Psychology and Psychiatry, 55-9 (September 2014)
[article]
Titre : Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder Type de document : Texte imprimé et/ou numérique Auteurs : Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur Article en page(s) : p.959-980 Langues : Anglais (eng) Mots-clés : Bipolar mania maintenance mood stabilizer antipsychotic child adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238
in Journal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980[article] Practitioner Review: Long-term pharmacological treatment of pediatric bipolar disorder [Texte imprimé et/ou numérique] / Covadonga M. DIAZ-CANEJA, Auteur ; Carmen MORENO, Auteur ; Cloe LLORENTE, Auteur ; Ana ESPLIEGO, Auteur ; Celso ARANGO, Auteur ; Dolores MORENO, Auteur . - p.959-980.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 55-9 (September 2014) . - p.959-980
Mots-clés : Bipolar mania maintenance mood stabilizer antipsychotic child adolescent Index. décimale : PER Périodiques Résumé : Background Although long-term treatment is a core aspect of the management of children and adolescents with bipolar disorder (BD), most clinical recommendations are based on results from short-term studies or adult data. In order to guide clinical practice, we review the efficacy and safety profile of mood stabilizers, antipsychotics, and other pharmacological strategies for the long-term treatment of BD in pediatric patients. Methods A MEDLINE, EMBASE, Cochrane and PsycInfo search (inception through November 2013) was performed to identify prospective studies longer than 12 weeks assessing the use of pharmacological strategies for the long-term treatment of BD in pediatric patients (0–18 years of age). Results Four randomized controlled trials (RCT) [three placebo-controlled (assessing aripiprazole (2) and flax oil), and one head-to-head comparison of lithium vs. divalproex], and thirteen noncontrolled studies (six open-label studies assessing lithium or anticonvulsants, five assessing second-generation antipsychotics (SGAs) and four assessing combination strategies) were included in the review. Aripiprazole has shown efficacy for relapse prevention in children with pediatric bipolar disorder (PBD) 4–9 years of age in one placebo-controlled RCT. Positive results have been reported in noncontrolled studies with quetiapine and lithium for relapse prevention, as well as with lithium, quetiapine, ziprasidone, and the combination of risperidone and divalproex or lithium for long-term symptom reduction in PBD. The most frequently reported adverse events in children and adolescents treated with lithium and anticonvulsants are gastrointestinal and neurological, whereas use of SGAs is mainly related to weight gain and sedation. Conclusion According to the limited empirical evidence, aripiprazole can be useful for relapse prevention in children with PBD. Given the lack of consistent efficacy data, clinical decision making should be based on individual clinical aspects and safety concerns. En ligne : http://dx.doi.org/10.1111/jcpp.12271 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=238